From: Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment
RA | OA | ReA | PsA | AS | SSc | SLE | Control | |
---|---|---|---|---|---|---|---|---|
Number | 98 | 58 | 13 | 30 | 30 | 40 | 56 | 97 |
Gender (F:M) | 72:26 | 29:29 | 5:8 | 19:11 | 5:25 | 27:13 | 48:8 | 64:33 |
Age * (years) | 55 (23-85) | 56 (36-65) | 29 (17-60) | 48 (23-70) | 41 (22-75) | 54 (16-77) | 42 (17-75) | 45 (23-74) |
Disease duration (years) | 7.9 (0.8-39) | Not available | 0.04 (0-0.19) | 6.3 (1.7-23.3) | 15.6 (0.2-55.2) | 1.5 (0.5-19) | 5.0 (0.35) | Not applicable |
COMP-C3b (AU) | 0.42 (0.19-1.19) | 0.58 (0.27-1.36) | 0.74 (0.38-1.14) | 0.31 (0.19-0.92) | 0.33 (0.18-0.51) | 0.76 (0.15-1.43) | 0.50 (0.27-0.85) | 0.20 (0.09-0.83) |
COMP (U/L) | 9.1 (3.3-24.4) | 11.2 (6.4-22.1) | 8.9 (4.4-11.2) | 8.2 (4.1-15.3) | 6.8 (3.4-12.4) | 10.5 (2.3-29.0) | 5.6 (3.0-13.3) | 7.0 (3.2-12.1) |
CRP (mg/L) | 15.5 (0-126) | < 5 (< 5-15) | Not determined | 9.3 (1-205) | 7.9 (0-65) | 12 (0.6-91) | Not determined | Not determined |
ESR (mm/h) | 29 (2-110) | 6 (1-35) | 48 (2-100) | 18 (4-95) | 14 (2-64) | 18 (2-90) | Not determined | Not determined |
TNF-α inhibitor infliximab/etanercept/adalimumab | 98/0/0 | 22/6/2 | 9/15/6 |